Crimean-Congo haemorrhagic fever (CCHF) has become an important problem in certain parts of the world. Cytokine storm plays a critical role in the pathogenesis of CCHF. Early diagnosis, supportive therapy and invasive monitoring are the cornerstones of the management of CCHF. Ribavirin is active against CCHF virus in vitro, however, evidence of clinical efficacy is still conflicting. Here, we describe a patient successfully recovered from CCHF with a combination of plasma exchange and ribavirin therapy.
Get full access to this article
View all access options for this article.
References
1.
LeblebiciogluH. Crimean-Congo haemorrhagic fever in Euroasia. Int J Antimicrob Agents2010(Suppl 1):S43–6
2.
Soares-WeiserK, ThomasS, ThomsonG, GarnerP. Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis. BMC Infect Dis2010;10:207
3.
WeberF, MirazimiA. Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis. Cytokine Growth Factor Rev2008;19:395–404
4.
KaynarL, AltuntasF, AydogduI, Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus Apher Sci2008;38:109–15
5.
BusundR, KouklineV, UtrobinU, NedashkovskyE. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med2002;28:1434–9
